Array BioPharma (NASDAQ:ARRY) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1 by 8 Brokerage Firm. 8 Wall Street Firms have rated the stock as a strong buys.
Other Equity analysts have also commented on the company shares. SunTrust Robinson Humphrey initiates coverage on Array BioPharma (NASDAQ:ARRY) . Analysts at the SunTrust Robinson Humphrey have a current rating of Buy on the shares. The rating by the firm was issued on June 3, 2016.
Array BioPharma (NASDAQ:ARRY): The mean estimate for the short term price target for Array BioPharma (NASDAQ:ARRY) stands at $8.33 according to 6 Analysts. The higher price target estimate for the stock has been calculated at $13 while the lower price target estimate is at $6.
Array BioPharma (NASDAQ:ARRY) rose 2.13% or 0.07 points on Tuesday and made its way into the gainers of the day. After trading began at $3.32 the stock was seen hitting $3.37 as a peak level and $3.24 as the lowest level. The stock ended up at $3.35. The daily volume was measured at 1,581,044 shares. The 52-week high of the share price is $8.04 and the 52-week low is $2.385. The company has a market cap of $481 million.
Shares of Array BioPharma Inc. rose by 1.82% in the last five trading days and 1.21% for the last 4 weeks. Array BioPharma Inc. is up 13.95% in the last 3-month period. Year-to-Date the stock performance stands at -20.62%.
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer. The Companys wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). In addition, the Company has 11 ongoing partner-funded clinical programs, including two MEK inhibitors, which are both in Phase III clinical trials, binimetinib with Novartis and selumetinib with AstraZeneca.